Seres Therapeutics, Inc. (MCRB) Earns Positive Rating from Analysts at Citigroup Inc.
Citigroup Inc. began coverage on shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) in a research note issued on Thursday, The Fly reports. The firm set a “positive” rating and a $19.00 price target on the biotechnology company’s stock. Citigroup Inc.’s target price points to a potential upside of 74.79% from the stock’s current price.
Several other research analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. Seaport Global Securities reissued a “buy” rating and set a $20.00 target price on shares of Seres Therapeutics in a research report on Friday, October 6th. Cowen and Company reissued a “buy” rating on shares of Seres Therapeutics in a research report on Monday, October 2nd. ValuEngine downgraded shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, September 21st. Finally, Cantor Fitzgerald reissued a “buy” rating on shares of Seres Therapeutics in a research report on Wednesday, August 30th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $17.71.
Shares of Seres Therapeutics (MCRB) traded down 0.91% during midday trading on Thursday, hitting $10.87. 166,243 shares of the company’s stock were exchanged. The firm’s market cap is $440.37 million. The stock’s 50-day moving average price is $14.35 and its 200 day moving average price is $14.35. Seres Therapeutics has a one year low of $8.85 and a one year high of $17.42.
Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.10). The company had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $3.00 million. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The company’s revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.70) earnings per share. Equities research analysts forecast that Seres Therapeutics will post ($2.55) EPS for the current year.
A number of large investors have recently modified their holdings of MCRB. Jennison Associates grew its position in Seres Therapeutics by 0.4% in the third quarter. Jennison Associates now owns 391,700 shares of the biotechnology company’s stock valued at $11,610,000 after acquiring an additional 1,700 shares in the last quarter. ProShare Advisors LLC acquired a new stake in Seres Therapeutics in the fourth quarter valued at approximately $1,146,000. Morgan Stanley grew its position in Seres Therapeutics by 225.3% in the fourth quarter. Morgan Stanley now owns 33,758 shares of the biotechnology company’s stock valued at $1,185,000 after acquiring an additional 23,381 shares in the last quarter. Jennison Associates LLC grew its position in Seres Therapeutics by 1.9% in the fourth quarter. Jennison Associates LLC now owns 398,959 shares of the biotechnology company’s stock valued at $13,999,000 after acquiring an additional 7,259 shares in the last quarter. Finally, BlackRock Advisors LLC grew its position in Seres Therapeutics by 0.7% in the fourth quarter. BlackRock Advisors LLC now owns 340,871 shares of the biotechnology company’s stock valued at $11,962,000 after acquiring an additional 2,443 shares in the last quarter. 74.76% of the stock is owned by institutional investors.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.